<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Lymph node (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e>) <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is a critical factor in making accurate prognoses and therapeutic decisions </plain></SENT>
<SENT sid="1" pm="."><plain>This study evaluated the clinical performance of the one-step nucleic acid amplification (OSNA) assay in accurately diagnosing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients through the specific detection of cytokeratin 19 mRNA levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LNs</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The OSNA assay was performed on 121 LNs dissected from early-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients (pStage 0 or I) or from patients with benign colorectal disease (study 1) </plain></SENT>
<SENT sid="3" pm="."><plain>Separately, 385 LNs were dissected from 85 CRC patients (any stage); the OSNA assay was performed on half of each <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e>, and the results were compared with histopathological examination in 2-mm intervals of the other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> half (study 2) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In study 1, <z:hpo ids='HP_0000001'>all</z:hpo> 121 histopathologically negative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LNs</z:e> were also negative by the OSNA assay (concordance rate for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> negative: 1.0, 95% confidence interval [95% CI]: 0.976-1.0) </plain></SENT>
<SENT sid="5" pm="."><plain>In study 2, the concordance rate between the OSNA assay and the 2-mm-interval histopathological examination was 0.971 (95% CI: 0.950-0.984), with a sensitivity of 0.952 (95% CI: 0.881-0.987) and a specificity of 0.977 (95% CI: 0.953-0.991) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: The OSNA assay provided a judgment performance equivalent to a 2-mm-interval histopathological examination, a more detailed assay than the common pathological examination </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, the OSNA assay is considered a new molecular examination method for the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients in clinical settings </plain></SENT>
</text></document>